Click to download or view mobile version Author(s): Abstract or description: More Virtual Posters Safety of a JAKi Across 15,000 Patient-Years of Data Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies Safety and Efficacy of a JAKi in Patients With Rheumatoid Arthritis Refractory to Biologic DMARDs: Results Through Week 204 From the SELECT-CHOICE Study
